Preventing Chronic Disease | Testing for Human Immunodeficiency Virus Among Cancer Survivors Under Age 65 in the United States - CDC

FULL-TEXT ►

Preventing Chronic Disease | Testing for Human Immunodeficiency Virus Among Cancer Survivors Under Age 65 in the United States - CDC

Testing for Human Immunodeficiency Virus Among Cancer Survivors Under Age 65 in the United States

Navigate This Article

• Abstract
• Introduction
• Methods
• Results
• Discussion
• Acknowledgments
• Author Information
• References
• Tables

Jun Li, MD, PhD,, MPH; Trevor D. Thompson, BS; Eric Tai, MD, MPH; Guixiang Zhao, MD, PhD; Alexandra M. Oster, MD, MPH

Suggested citation for this article: Li J, Thompson TD, Tai E, Zhao G, Oster AM. Testing for Human Immunodeficiency Virus Among Cancer Survivors Under Age 65 in the United States. Prev Chronic Dis 2014;11:140274. DOI: http://dx.doi.org/10.5888/pcd11.140274.

PEER REVIEWED

Abstract

Introduction
Knowing the human immunodeficiency virus (HIV) serostatus of patients at the time of cancer diagnosis or cancer recurrence is prerequisite to coordinating HIV and cancer treatments and improving treatment outcomes. However, there are no published data about HIV testing among cancer survivors in the United States. We sought to provide estimates of the proportion of cancer survivors tested for HIV and to characterize factors associated with having had HIV testing.

Methods
We used data from the 2009 Behavioral Risk Factor Surveillance System to calculate the proportion of cancer survivors under age 65 who had undergone HIV testing, by demographic and health-related factors and by state. Adjusted proportion estimates were calculated by multivariable logistic regression.

Results
Only 41% of cancer survivors in the United States under the age of 65 reported ever having had an HIV test. The highest proportion of survivors tested was among patients aged 25 to 34 years (72.2%), non-Hispanic blacks (59.5%), cervical cancer survivors (51.2%). The proportion tested was highest in the District of Columbia (68.3%) and lowest in Nebraska (24.1%). Multivariable analysis showed that factors associated with HIV testing included being non-Hispanic black or Hispanic, being younger, having higher education, not being married or living with a partner, not being disabled, and having medical cost concerns. Having an AIDS-defining cancer was associated with HIV testing only among females.

Conclusion
The proportions of HIV testing varied substantially by demographic and health-related factors and by state. Our study points to the need for public health interventions to promote HIV testing among cancer survivors.

Acknowledgments

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention. Authors have no financial support or competing interest to declare.

Top of Page

Author Information

Corresponding Author: Jun Li, MD, PhD, MPH, Epidemiologist, Division of Cancer Prevention and Control, Centers for Disease Control and Prevention, 4770 Buford Hwy, MS F76, Atlanta, GA 30341. Telephone: 770-488-3030. E-mail: ffa2@cdc.gov.

Author Affiliations: Trevor D. Thompson, Eric Tai, Guixiang Zhao, Alexandra M. Oster, Centers for Disease Control and Prevention, Atlanta, Georgia.

Top of Page

References

1. Estimated HIV incidence in the United States, 2007–2010. HIV surveillance supplemental report. Atlanta (GA): Centers for Disease Control and Prevention; 2012. http://www.cdc.gov/hiv/topics/surveillance/resources/reports/#supplement. Accessed November 30, 2013.
2. Monitoring selected national HIV prevention and care objectives by using HIV surveillance data — United States and 6 US dependent areas – 2011. HIV surveillance supplemental report. Atlanta (GA): Centers for Disease Control and Prevention; 2013. http://www.cdc.gov/hiv/library/reports/surveillance/. Accessed January 31, 2014.
3. Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006;55(RR-14):1–17. PubMed
4. Engels EA, Biggar RJ, Hall HI, Cross H, Crutchfield A, Finch JL, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123(1):187–94. CrossRef PubMed
5. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT, et al. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and among children aged 18 months to <13 years — United States, 2008. MMWR Recomm Rep 2008;57(RR-10):1–12. PubMed
6. Shiels MS, Cole SR, Kirk GD, Poole C. A meta-analysis of the incidence of non-AIDS cancers in HIV-infected individuals. J Acquir Immune Defic Syndr 2009;52(5):611–22. PubMed
7. SEER Cancer Statistics Review. 1975–2010. Bethesda (MD): National Cancer Institute; 2012. http://seer.cancer.gov/csr/1975_2010/. Accessed July 5, 2013.
8. Centers for Disease Control and Prevention. Cancer survivors — United States, 2007. MMWR Morb Mortal Wkly Rep 2011;60(9):269–72. PubMed
9. de Moor JS, Mariotto AB, Parry C, Alfano CM, Padgett L, Kent EE, et al. Cancer survivors in the United States: prevalence across the survivorship trajectory and implications for care. Cancer Epidemiol Biomarkers Prev 2013;22(4):561–70. CrossRef PubMed
10. Patel P, Armon C, Chmiel JS, Brooks JT, Buchacz K, Wood K, et al. Factors associated with cancer incidence and with all-cause mortality after cancer diagnosis among human immunodeficiency virus–infected persons during the combination antiretroviral therapy era. Open Forum Infectious Disease; 2014. http://ofid.oxfordjournals.org/content/1/1/ofu012.abstract. Accessed August 20, 2014.
11. Chiao EY, Dezube BJ, Krown SE, Wachsman W, Brock MV, Giordano TP, et al. Time for oncologists to opt in for routine opt-out HIV testing? JAMA 2010;304(3):334–9. CrossRef PubMed
12. Behavioral Risk Factor Surveillance System summary data quality report. Atlanta (GA): Centers for Disease Control and Prevention; 2009. http://www.cdc.gov/brfss/annual_data/annual_2009.htm. Accessed July 11, 2013.
13. HIV testing trends in the United States. 2000–2011. Atlanta (GA): Centers for Disease Control and Prevention; 2013. http://www.cdc.gov/hiv/pdf/testing_trends.pdf. Accessed July 2, 2013.
14. Cave J, Edwards SG, Miller RF, Ardeshna KM, Lee SM. Should we implement “opt-out” HIV testing for patients with lymphoma? Clin Med 2009;9(4):320–2.CrossRef PubMed
15. Moyer VA. US Preventive Service Task Force. Screening for HIV: US Preventive Services Task Force recommendation statement. Ann Intern Med 2013;159(1):51–60. PubMed
16. Neri SV, Bradley EH, Groce NE. Frequency of HIV testing among persons with disabilities: results from the National Health Interview Survey, 2002. AIDS Educ Prev 2007;19(6):545–54. CrossRef PubMed
17. Bartlett JG, Branson BM, Fenton K, Hauschild BC, Miller V, Mayer KH. Opt-out testing for human immunodeficiency virus in the United States: progress and challenges. JAMA 2008;300(8):945–51. CrossRef PubMed
18. Burke RC, Sepkowitz KA, Bernstein KT, Karpati AM, Myers JE, Tsoi BW, et al. Why don’t physicians test for HIV? A review of the US literature. AIDS 2007;21(12):1617–24. CrossRef PubMed
19. Schwarcz S, Richards TA, Frank H, Wenzel C, Hsu LC, Chin CS, et al. Identifying barriers to HIV testing: personal and contextual factors associated with late HIV testing. AIDS Care 2011;23(7):892–900. CrossRef PubMed
20. Medicare expands list of covered preventive services to include HIV screening tests. Washington (DC): US Department of Health and Human Services; 2009. http://www.medicalwebtimes.com/read/medicare_expands_list_of_covered_preventive_services_to_include_hiv_screening_tests. Accessed July 1, 2013.
21. Patel P, Hanson DL, Sullivan PS, Novak RM, Moorman AC, Tong TC, et al. Incidence of types of cancer among HIV-infected persons compared with the general population in the United States, 1992–2003. Ann Intern Med 2008;148(10):728–36. CrossRef PubMed
22. Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103(9):753–62. CrossRef PubMed
23. Bini EJ, Park J, Francois F. Use of flexible sigmoidoscopy to screen for colorectal cancer in HIV-infected patients 50 years of age and older. Arch Intern Med 2006;166(15):1626–31. CrossRef PubMed
24. Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001;285(13):1736–45. CrossRef PubMed
25. Forastiere A, Koch W, Trotti A, Sidransky D. Head and neck cancer. N Engl J Med 2001;345(26):1890–900. CrossRef PubMed
26. Moradpour D, Blum HE. Pathogenesis of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2005;17(5):477–83. CrossRef PubMed
27. Wistuba II, Behrens C, Gazdar AF. Pathogenesis of non-AIDS–defining cancers: a review. AIDS Patient Care STDS 1999;13(7):415–26. CrossRef PubMed
28. Tesoriero JM, Gieryic SM, Carrascal A, Lavigne HE. Smoking among HIV positive New Yorkers: prevalence, frequency, and opportunities for cessation. AIDS Behav 2010;14(4):824–35. CrossRef PubMed
29. Centers for Disease Control and Prevention. Missed opportunities for earlier diagnosis of HIV infection — South Carolina, 1997–2005. MMWR Morb Mortal Wkly Rep 2006;55(47):1269–72. PubMed
30. Keruly JC, Moore RD. Immune status at presentation to care did not improve among antiretroviral-naive persons from 1990 to 2006. Clin Infect Dis 2007;45(10):1369–74. CrossRef PubMed